{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"71.1","upperLimit":"88.5","value":"79.8"},{"groupId":"OG001","lowerLimit":"74.1","upperLimit":"92.2","value":"83.2"},{"groupId":"OG002","lowerLimit":"40.9","upperLimit":"92.5","value":"66.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"48"},{"groupId":"OG002","value":"9"}],"units":"Participants"}],"description":"An event is defined as: Induction failure, relapse at any site, secondary malignancy, or death.","dispersionType":"90% Confidence Interval","groups":[{"description":"See Detailed Description\n\nAsparaginase: Given IT\n\nCyclophosphamide: Given IV\n\nCytarabine: Given IT or IV\n\nDasatinib: Given PO\n\nDaunorubicin Hydrochloride: Given IV\n\nDexamethasone: Given IV or PO\n\nEtoposide: Given IV\n\nFilgrastim: Given IV or SC\n\nHydrocortisone Sodium Succinate: Given IT\n\nIfosfamide: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nLeucovorin Calcium: Given IV or PO\n\nMercaptopurine: Given PO\n\nMethotrexate: Given IT, PO, or IV\n\nMethylprednisolone: Given IV\n\nPegaspargase: Given IM\n\nPrednisone: Given PO or IV\n\nRadiation Therapy: Some patients undergo cranial RT\n\nVincristine Sulfate: Given IV","id":"OG000","title":"Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy)"},{"description":"Based on Minimal Residual Disease, less than 1%.","id":"OG001","title":"Standard-risk"},{"description":"Based on Minimal Residual Disease, great than or equal to 1%.","id":"OG002","title":"High-risk"}],"paramType":"NUMBER","populationDescription":"Included in the analysis are two patients who received the drug therapy but were not risk classified.","reportingStatus":"POSTED","timeFrame":"From the time entry on study to first event or date of last follow-up, assessed up to 7 years","title":"Overall EFS Rate for the Combined Cohort of Standard- and High-Risk Patients (Who Receive the Final Chosen Dose of Dasatinib)","type":"SECONDARY","unitOfMeasure":"percentage of patients"}